{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:01:58Z","timestamp":1794376918604,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The COMPOSUR study is evaluating vibegron for the treatment of overactive bladder (OAB) in a real-world setting. We report results of a prespecified 6-month interim analysis, assessing patient-reported treatment satisfaction, persistence, safety, and tolerability over the first 6\u00a0months after receiving a new prescription for vibegron.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>COMPOSUR (NCT05067478) is a 12-month, phase 4 study of vibegron. Patients were enrolled if they were\u2009\u2265\u200918\u00a0years of age with OAB, initiating vibegron after previously receiving anticholinergics (Cohort A) or mirabegron with\/without anticholinergics (Cohort B). Satisfaction was assessed via the OAB Satisfaction With Treatment Questionnaire (OAB-SAT-q; domain scores on 0\u2212100 scale, higher scores denoting greater satisfaction). The primary endpoint is the OAB-SAT-q satisfaction domain score. The key secondary endpoints are the percentage of positive responses to OAB-SAT-q questions 1\u20133 and 11. Additional secondary endpoints include OAB-SAT-q scores for side effects, endorsement, preference, and convenience. Persistence was assessed as an exploratory endpoint. Safety was assessed via adverse events (AEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 403 patients were enrolled and initiated treatment with vibegron; 104 patients discontinued the study before month 6, most commonly owing to withdrawal of consent (<jats:italic>n<\/jats:italic>\u2009=\u200932) and AEs (<jats:italic>n<\/jats:italic>\u2009=\u20098). Mean (SD) patient age was 56.1 (12.5) years, and 29% were male. Overall, at 6\u00a0months, mean (SD) OAB-SAT-q domain scores were 70.0 (21.9) for satisfaction, 84.7 (20.6) for convenience, 91.1 (16.4) for side effects, and 80.4 (20.6) for endorsement. At 6\u00a0months, 85.6% (95% CI, 81.1%\u201390.1%) of patients preferred vibegron to previous OAB treatment. Most patients responded positively to individual OAB-SAT-questions; outcomes were similar from months 1 to 6 and in Cohorts A and B. Persistence with vibegron treatment at 6\u00a0months was 73.9% (95% CI, 69.3%\u201378.0%). Overall, 33.5% of patients experienced a treatment-emergent AE, most commonly (\u2265\u20092% overall) urinary tract infection (4.0%), headache (2.7%), and dizziness (2.2%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>As of the 6-month interim analysis of the COMPOSUR study, most patients receiving vibegron were satisfied with treatment; satisfaction generally persisted from month 1 to 6, regardless of prior OAB treatment received. Treatment with vibegron was generally safe and well tolerated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov identifier: NCT05067478; registered: October 5, 2021.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12894-025-01742-6","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:35:30Z","timestamp":1743716130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR study"],"prefix":"10.1186","volume":"25","author":[{"given":"Roger R.","family":"Dmochowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rovner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane K.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Abedinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"1","key":"1742_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11\u201320.","journal-title":"J Urol"},{"issue":"4","key":"1742_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","volume":"7","author":"KS Coyne","year":"2004","unstructured":"Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, Hunt TL. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455\u201363.","journal-title":"Value Health"},{"issue":"11","key":"1742_CR3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"issue":"6","key":"1742_CR4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"9","key":"1742_CR5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/JOM.0000000000001367","volume":"60","author":"E Durden","year":"2018","unstructured":"Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The direct and indirect costs associated with overactive bladder within a commercially-insured population in the United States. J Occup Environ Med. 2018;60(9):847\u201352.","journal-title":"J Occup Environ Med"},{"issue":"4","key":"1742_CR6","first-page":"406","volume":"22","author":"A Yehoshua","year":"2016","unstructured":"Yehoshua A, Chancellor M, Vasavada S, Malone DC, Armstrong EP, Joshi M, et al. Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm. 2016;22(4):406\u201313.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"1742_CR7","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","volume":"35","author":"SM Szabo","year":"2018","unstructured":"Szabo SM, Gooch KL, Walker DR, Johnston KM, Wagg AS. The association between overactive bladder and falls and fractures: a systematic review. Adv Ther. 2018;35(11):1831\u201341.","journal-title":"Adv Ther"},{"issue":"1","key":"1742_CR8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1359105314522084","volume":"21","author":"D Kinsey","year":"2016","unstructured":"Kinsey D, Pretorius S, Glover L, Alexander T. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2016;21(1):69\u201381.","journal-title":"J Health Psychol"},{"key":"1742_CR9","doi-asserted-by":"crossref","unstructured":"Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023;5(5):Cd003781.","DOI":"10.1002\/14651858.CD003781.pub3"},{"issue":"5","key":"1742_CR10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","volume":"148","author":"P Abrams","year":"2006","unstructured":"Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565\u201378.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"1742_CR11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"G Yeowell","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11): e021889.","journal-title":"BMJ Open"},{"issue":"9","key":"1742_CR12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276\u201382.","journal-title":"BJU Int"},{"issue":"8","key":"1742_CR13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084\u201393.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1742_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"RR Dmochowski","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K, Enemchukwu E, Tee S, Varano S, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40(1):28\u201337.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1742_CR15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ageing\/afaa090","volume":"49","author":"NT Pieper","year":"2020","unstructured":"Pieper NT, Grossi CM, Chan WY, Loke YK, Savva GM, Haroulis C, et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing. 2020;49(6):939\u201347.","journal-title":"Age Ageing"},{"issue":"1","key":"1742_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","volume":"126","author":"B Welk","year":"2020","unstructured":"Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183\u201390.","journal-title":"BJU Int"},{"issue":"2","key":"1742_CR17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/jcm12020396","volume":"12","author":"A Cicione","year":"2023","unstructured":"Cicione A, Lombardo R, Umbaca V, Tema G, Gallo G, Stira J, et al. Patients\u2019 preferences and expectations in overactive bladder: a systematic review. J Clin Med. 2023;12(2):396.","journal-title":"J Clin Med."},{"key":"1742_CR18","unstructured":"Sumitomo Pharma America, Inc. GEMTESA\u00ae (vibegron). Full prescribing information. Marlborough, MA: Sumitomo Pharma America, Inc.; 2024."},{"issue":"2","key":"1742_CR19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"1","key":"1742_CR20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12894-023-01240-7","volume":"23","author":"RR Dmochowski","year":"2023","unstructured":"Dmochowski RR, Rovner ES, Kennelly MJ, Newman DK, Abedinzadeh L, Snyder D, et al. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder. BMC Urol. 2023;23(1):64.","journal-title":"BMC Urol"},{"key":"1742_CR21","unstructured":"Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 1 ed. New York: Wiley; 1980."},{"issue":"5","key":"1742_CR22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/03007995.2017.1419170","volume":"34","author":"R Freeman","year":"2018","unstructured":"Freeman R, Foley S, Rosa Arias J, Vicente E, Grill R, Kachlirova Z, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018;34(5):785\u201393.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1742_CR23","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/nau.24505","volume":"39","author":"KJ Ko","year":"2020","unstructured":"Ko KJ, Choo MS, Chang YS, Kim JC, Lee KS. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study). Neurourol Urodyn. 2020;39(8):2417\u201324.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1742_CR24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/nau.22943","volume":"36","author":"N Pindoria","year":"2017","unstructured":"Pindoria N, Malde S, Nowers J, Taylor C, Kelleher C, Sahai A. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn. 2017;36(2):404\u20138.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1742_CR25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","volume":"8","author":"YF Yu","year":"2005","unstructured":"Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the california medicaid program. Value Health. 2005;8(4):495\u2013505.","journal-title":"Value Health"},{"issue":"4","key":"1742_CR26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/luts.12382","volume":"13","author":"KV Carlson","year":"2021","unstructured":"Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425\u201334.","journal-title":"Low Urin Tract Symptoms"},{"issue":"7","key":"1742_CR27","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/nau.25478","volume":"43","author":"B Chastek","year":"2024","unstructured":"Chastek B, Carrera A, Landis C, Snyder D, Abedinzadeh L, Bancroft T, et al. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: a retrospective claims study. Neurourol Urodyn. 2024;43(7):1504\u201313.","journal-title":"Neurourol Urodyn"},{"key":"1742_CR28","first-page":"1","volume":"364","author":"Y Ostchega","year":"2020","unstructured":"Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: united states, 2017\u20132018. NCHS Data Brief. 2020;364:1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"2","key":"1742_CR29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-410X.2009.09073.x","volume":"106","author":"KE Andersson","year":"2010","unstructured":"Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010;106(2):268\u201374.","journal-title":"BJU Int"},{"issue":"4","key":"1742_CR30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","volume":"109","author":"CV Asche","year":"2012","unstructured":"Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 2012;109(4):572\u201380.","journal-title":"BJU Int"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01742-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T19:19:15Z","timestamp":1743967155000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01742-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01742-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\/Good Clinical Practice guidelines. Investigators received institutional review board, research ethics board, or independent ethics committee approval before the initiation of the study. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RRD is a consultant for Sumitomo Pharma America, Inc. ESR is a consultant for Sumitomo Pharma America, Inc., and Hologic and has received research funding from Allergan, Medtronic, and Uromedica. MJK is a consultant for AbbVie, Boston Scientific, Coloplast, Laborie, and Sumitomo Pharma America, Inc., and has received grant or research study funding from AbbVie, Axonics, Boston Scientific, Coloplast, and Cook Myosite. DKN is an editor at Digital Science Press; consultant for COSM, Convatec, and Sumitomo Pharma America, Inc.; and has received funding from Convatec and the National Institutes of Health. KX is an investigator for Sumitomo Pharma America, Inc., and is a consultant to and has received research funding from Medtronic. LA is an employee of Sumitomo Pharma America, Inc. ET and DS were employees of Sumitomo Pharma America, Inc., at the time the study was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}